1 |
NCT02986698 |
Recruiting |
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) |
- Alpha Thalassemia Major
- Hemoglobinopathy; With Thalassemia
- Hemoglobinopathies
- (and 6 more...)
|
- Biological: in utero hematopoietic stem cell transplantation
|
Interventional |
Phase 1 |
- University of California, San Francisco
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maternal participant tolerance of bone marrow harvest
- Safety of in utero hematopoietic stem cell transplantation when performed at the same time as in utero blood transfusion for the fetal participant
- Adequate bone marrow harvest from the maternal participant
- successful engraftment
|
10 |
All |
18 Weeks to 25 Weeks (Child) |
NCT02986698 |
16-21157 |
|
October 5, 2017 |
February 2022 |
February 2024 |
December 8, 2016 |
October 6, 2017 |
|
- University of California
San Francisco, California, United States
|
2 |
NCT03283111 |
Not yet recruiting |
Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma |
|
- Biological: autologous stem cell transplantation
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall survival
|
150 |
All |
18 Years to 65 Years (Adult) |
NCT03283111 |
CSCO-LWP |
|
September 2017 |
December 2018 |
December 2018 |
September 14, 2017 |
September 14, 2017 |
|
|
3 |
NCT03000296 |
Recruiting |
Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease |
- Crohn Disease
- Inflammatory Bowel Diseases
- Gastroenteritis
|
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
|
Interventional |
Phase 1 Phase 2 |
- Beneficência Portuguesa de São Paulo
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of unselected autologous HSCT in refractary Crohn´s patients
- CDAI
- CRAIG CSS
- (and 6 more...)
|
20 |
All |
14 Years to 70 Years (Child, Adult, Senior) |
NCT03000296 |
autocrohnproject1 |
AutoChron |
October 2013 |
December 2016 |
March 2018 |
December 22, 2016 |
December 22, 2016 |
|
- Beneficencia Portuguesa
Sao Jose do Rio Preto, SP, Brazil
|
4 |
NCT02759822 |
Recruiting |
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias |
- Leukemia, Myeloid, Acute
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
- Procedure: Haploidentical Stem Cell Transplantation
|
Observational |
|
- Leonardo Javier Arcuri
- Instituto Nacional de Cancer, Brazil
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Overall Survival
- Cumulative incidence of leukemia relapse
- Transplant Related Mortality
- (and 3 more...)
|
30 |
All |
1 Year to 60 Years (Child, Adult) |
NCT02759822 |
CEMO/INCA-Haplo-01 |
|
April 2016 |
April 2021 |
|
May 3, 2016 |
May 3, 2016 |
|
- Instituto Nacional de Cancer
Rio de Janeiro, Brazil
|
5 |
NCT01374841 |
Recruiting |
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors |
|
- Drug: Cyclophosphamide
- Other: Hematopoietic Stem Cell Transplantation,
|
Interventional |
Phase 2 |
- European Institute of Oncology
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Donor engraftment
- Incidence and severity of graft versus host disease
- Non-relapse-related mortality
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01374841 |
IEO S513/110 2009-018083-94 |
|
August 2010 |
August 2019 |
December 2019 |
June 16, 2011 |
August 10, 2016 |
|
- European Institute of Oncology
Milan, Italy
|
6 |
NCT02943889 |
Not yet recruiting |
Stem Cell Transplantation in Cirrhotic Patients |
|
- Biological: Mesenchymal stem cell transplantation
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement of liver function in form of improvement in child score
- Postpone or to overcome liver transplantation complications
|
40 |
All |
Child, Adult, Senior |
NCT02943889 |
SCT-LC |
|
October 2016 |
June 2017 |
August 2017 |
October 25, 2016 |
October 25, 2016 |
|
|
7 |
NCT00716690 |
Recruiting |
Multi Donor Mismatched Stem Cell Transplantation (MDT) |
- Graft-Versus-Host Disease
|
- Procedure: Multi donor stem cell transplantation
|
Interventional |
Phase 1 Phase 2 |
- Hadassah Medical Organization
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Day of neutrophil engraftment
- Day of platelet engraftment>20x10(9)L
- Acute GVHD occurrence>2
- (and 9 more...)
|
10 |
All |
up to 70 Years (Child, Adult, Senior) |
NCT00716690 |
MYS-04-HMO-CTIL |
|
July 2008 |
January 2020 |
June 2020 |
July 16, 2008 |
February 19, 2016 |
|
- Hadassah Medical Organization
Jerusalem, Israel
|
8 |
NCT01597219 |
Recruiting |
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers |
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Acute Myeloid Leukaemia
- (and 6 more...)
|
- Procedure: Reduced intensity haplodentical stem cell transplant
- Procedure: Myeloablative haploidentical stem cell transplant
|
Interventional |
Phase 2 |
- University College, London
- Bloodwise
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
78 |
All |
16 Years to 70 Years (Child, Adult, Senior) |
NCT01597219 |
UCL/10/0411 |
UK-Haplo |
March 2013 |
March 2018 |
March 2020 |
May 11, 2012 |
April 27, 2017 |
|
- Birmingham Heartlands
Birmingham, United Kingdom - Bristol Royal Infirmary
Bristol, United Kingdom - Addenbrooke's Hospital
Cambridge, United Kingdom - (and 9 more...)
|
9 |
NCT02176434 |
Recruiting |
Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease |
|
- Procedure: Kidney and hematopoietic stem cell transplantation
- Biological: hematopoietic stem cell
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Renal allograft acceptance and ability to discontinue immunosuppressive therapy at 1 year
- Engraftment of hematopoietic stem cells (chimerism)
- Absence of graft versus host disease
- (and 4 more...)
|
10 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02176434 |
swisstolerance.ch |
|
September 2015 |
August 2019 |
August 2020 |
June 27, 2014 |
May 8, 2017 |
|
- University Hospital Zurich
Zurich, Switzerland
|
10 |
NCT02566395 |
Recruiting |
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies |
- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- (and 3 more...)
|
- Radiation: Radiation
- Drug: Cyclophosphamide
- Biological: Donor Lymphocyte Infusion (DLI)
- Biological: Haploidentical Stem Cell Transplantation
|
Interventional |
Phase 3 |
- Northwell Health
- New York Blood Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hematopoietic engraftment
- 2-Year disease-free survival
- Grade II-IV GvHD
- (and 2 more...)
|
10 |
All |
2 Years to 21 Years (Child, Adult) |
NCT02566395 |
14-551 |
|
December 2014 |
December 2019 |
December 2020 |
October 2, 2015 |
February 15, 2018 |
|
- Cohen Children's Medical Center
New Hyde Park, New York, United States
|
11 |
NCT03279094 |
Recruiting |
Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease |
|
- Biological: Hematopoietic stem cell transplantation
|
Interventional |
Phase 1 |
- City of Hope Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of unacceptable adverse events that are defined as any of the following events that occur from start of pre-transplant immunosuppressive therapy to the first 100 days post HCT:
- Time to donor neutrophil engraftment
- Time to donor platelets engraftment
- (and 10 more...)
|
15 |
All |
1 Year to 30 Years (Child, Adult) |
NCT03279094 |
17136 |
|
February 2, 2018 |
February 2023 |
February 2023 |
September 12, 2017 |
February 14, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States
|
12 |
NCT00787722 |
Recruiting |
Hematopoietic Stem Cell Transplant in Devic's Disease |
|
- Procedure: Hematopoietic stem cell transplantation
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival
- Visual Acuity
- Decreased weakness in limb (MRS)
- (and 6 more...)
|
40 |
All |
16 Years to 65 Years (Child, Adult) |
NCT00787722 |
DIAD Devic's Disease Auto 2008 |
|
October 2008 |
October 2017 |
October 2018 |
November 7, 2008 |
July 21, 2017 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
|
13 |
NCT03088709 |
Recruiting |
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide |
- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Myelodysplastic Syndrome
- (and 2 more...)
|
- Drug: Cyclophosphamide
- Drug: Tacrolimus
- Drug: Mycophenolate mofetil
- Other: Haploidentical Stem Cell Transplantation
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Chimerism
- Neutrophil engraftment
- Platelet engraftment
- (and 6 more...)
|
40 |
All |
16 Years to 90 Years (Child, Adult, Senior) |
NCT03088709 |
208941 |
|
January 18, 2017 |
January 31, 2020 |
January 31, 2021 |
March 23, 2017 |
October 13, 2017 |
|
- Loyola University Medical Center
Maywood, Illinois, United States
|
14 |
NCT02688049 |
Recruiting |
NeuroRegen Scaffold™ Combined With Stem Cells for Chronic Spinal Cord Injury Repair |
|
- Biological: NeuroRegen scaffold/mesenchymal stem cells transplantation
- Biological: NeuroRegen scaffold/neural stem cells transplantation
|
Interventional |
Phase 1 Phase 2 |
- Chinese Academy of Sciences
- Affiliated Hospital of Logistics University of CAPF
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Improvements in ASIA (American Spinal Injury Association) Impairment Scale
- Improvements in Somatosensory Evoked Potentials (SSEP)
- Improvements in Motor Evoked Potentials (MEP)
- (and 4 more...)
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT02688049 |
CAS-XDA-MNSCI/IGDB |
|
January 2016 |
June 2018 |
June 2018 |
February 23, 2016 |
June 2, 2017 |
|
- Affiliated Hospital of Logistics Universtiy of CAPF
Tianjin, China
|
15 |
NCT03209986 |
Recruiting |
Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis |
|
- Procedure: mesenchymal stem cell transplantation via peripheral vein
- Other: mesenchymal stem cell
|
Interventional |
Not Applicable |
- Xijing Hospital of Digestive Diseases
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Efficacy: Change of liver functions as assessed by MELD score
- Safety: Adverse events as assessed according to CTCAE 4.03
- Survival Benefit: Survival Rate at different time points
- (and 2 more...)
|
200 |
All |
18 Years to 65 Years (Adult) |
NCT03209986 |
XJMSC0001 |
|
August 1, 2017 |
June 30, 2019 |
December 31, 2019 |
July 6, 2017 |
July 6, 2017 |
|
- Xijing Hospital of Digestive Disease, Xijing Hospital
Xi'an, Shaanxi, China
|
16 |
NCT01895244 |
Recruiting |
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis |
- Scleroderma
- Cardiac Involvement
- Autologous Stem Cell Transplantation
|
- Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
|
Interventional |
Phase 2 |
- University Hospital Tuebingen
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Treatment related mortality
- Time to engraftment
- (and 2 more...)
|
44 |
All |
18 Years to 65 Years (Adult) |
NCT01895244 |
AST MOMA |
AST-MOMA |
September 2012 |
September 2018 |
September 2020 |
July 10, 2013 |
October 25, 2016 |
|
- University Hospital Tuebingen; Department of oncology, hematology, rheumatology, immunology and pulmology
Tuebingen, Germany
|
17 |
NCT02282514 |
Recruiting |
Stem Cell Transplantation for Stiff Person Syndrome (SPS) |
|
- Biological: Autologous Hematopoietic Stem Cells
- Drug: Cyclophosphamide
- Drug: Mesna
- (and 4 more...)
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Reduction of muscle relaxation anti-spasmatic medications
- Improvement of Chronic Pain Acceptance Questionnaire (CPAQ)
- (and 4 more...)
|
40 |
All |
18 Years to 60 Years (Adult) |
NCT02282514 |
DIAD.SPS.2014 |
SPS |
October 2014 |
October 2020 |
October 2021 |
November 4, 2014 |
March 29, 2018 |
|
- Northwestern University
Chicago, Illinois, United States
|
18 |
NCT00750971 |
Recruiting |
Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST) |
- Systemic Lupus Erythematosus
|
- Procedure: Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
|
Interventional |
Phase 2 |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- SLEDAI
- Serologic response (autoantibodies)
- Immune Reconstitution
- Organ-specific response parameters
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT00750971 |
CT-1306 |
ASSIST |
August 2008 |
July 2020 |
August 2020 |
September 11, 2008 |
March 20, 2017 |
|
- Universitätsmedizin Charité
Berlin, Germany - Universitätsklinik Düsseldorf
Düsseldorf, Germany - Universitätsklinikum Essen
Essen, Germany - (and 5 more...)
|
19 |
NCT02519114 |
Recruiting |
Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma |
|
- Procedure: Donor Bone Marrow stem cell transplantation
|
Interventional |
Phase 1 Phase 2 |
- Maastricht University Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (scale)
- Response rate (scale)
- Incidence of graft failure, engraftment and time to neutrophil and platelet recovery (hematology)
- (and 7 more...)
|
24 |
All |
18 Years to 60 Years (Adult) |
NCT02519114 |
NL49476.000 |
|
August 2015 |
June 2017 |
June 2017 |
August 10, 2015 |
February 10, 2017 |
|
- Maastricht university Medical center
Maastricht, Netherlands
|
20 |
NCT03366350 |
Recruiting |
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies |
- Acute Lymphoblastic Leukemia
- B Cell Lymphoma
|
- Genetic: Second generation CAR-T cells
- Procedure: Hematological stem cell transplantation
|
Interventional |
Phase 1 Phase 2 |
- Wuhan Sian Medical Technology Co., Ltd
- Wuhan Union Hospital, China
- Jingzhou Central Hospital
- (and 2 more...)
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of study related adverse events
- Number of participants with an MRD negative complete remission after CAR-T therapy and HSCT
|
30 |
All |
up to 70 Years (Child, Adult, Senior) |
NCT03366350 |
CART-CD19-02 |
|
January 1, 2018 |
January 1, 2021 |
June 1, 2021 |
December 8, 2017 |
January 23, 2018 |
|
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
|
21 |
NCT03366324 |
Recruiting |
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies |
- Acute Lymphoblastic Leukemia
- B Cell Lymphoma
|
- Genetic: Second generation CAR-T cells
- Procedure: Hematological stem cell transplantation
|
Interventional |
Phase 1 |
- Wuhan Sian Medical Technology Co., Ltd
- Wuhan Union Hospital, China
- Jingzhou Central Hospital
- (and 2 more...)
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of study related adverse events
- Number of participants with an MRD negative complete remission after CAR-T therapy and HSCT
|
20 |
All |
up to 70 Years (Child, Adult, Senior) |
NCT03366324 |
CART-CD19-03 |
|
January 1, 2018 |
January 1, 2021 |
June 1, 2021 |
December 8, 2017 |
January 23, 2018 |
|
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
|
22 |
NCT03295058 |
Not yet recruiting |
Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients |
|
- Drug: Conditioning regimen
- Drug: GVHD Prophylaxis
- Procedure: Allogenic Stem Cell Transplantation
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival rate
- GVHD occurrence (Acute or Chronic), engraftment and transplant related mortality
- Relapse rate
- Progression free survival
|
50 |
All |
16 Years to 50 Years (Child, Adult) |
NCT03295058 |
OPALLSCT |
|
December 1, 2017 |
December 1, 2019 |
June 2020 |
September 27, 2017 |
September 27, 2017 |
|
|
23 |
NCT03233659 |
Recruiting |
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation |
- Allogeneic Stem Cell Transplantation
- GVHD
|
|
Observational |
|
- Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The primary endpoint of study is detection of circulating cells by flow cytometry before and after Allogeneic Stem Cell Transplantation
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT03233659 |
IMM-2011-01 |
|
August 12, 2014 |
June 2018 |
June 2018 |
July 28, 2017 |
July 28, 2017 |
|
- Mario Arpinati
Bologna, Italy
|
24 |
NCT02098512 |
Recruiting |
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients |
|
- Drug: Brentuximab Vedotin
- Procedure: Allogeneic Stem Cell Transplantation
- Drug: Reduced Intensity Conditioning
|
Interventional |
Phase 1 Phase 2 |
- New York Medical College
- St. Baldrick's Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety
- Overall Survival
- To assess feasibility of developing a bank of LMP-specific CTLs from healthy donors
|
20 |
All |
up to 45 Years (Child, Adult) |
NCT02098512 |
NYMC 564 |
|
March 2014 |
December 2018 |
December 2019 |
March 28, 2014 |
March 29, 2018 |
|
- New York Medical College
Valhalla, New York, United States
|
25 |
NCT01087294 |
Recruiting |
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation |
- Leukemia, B-cell
- Lymphoma, Hodgkins
- Lymphoma, Non-hodgkins
- Lymphoma, B-Cell
|
- Procedure: Allogeneic stem cell transplant
- Biological: Anti-CD19-chimeric-antigen-receptor- transduced T cell
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the safety of allogeneic anti-CD19-CAR
- To determine if administering anti-CD19-CAR-transduced T cells from the original transplant donor can cause regression of B-cell malignancies that are relapsed or persistent after alloHSCT
- To measure the persistence of anti-CD 19-CAR-transduced T cells in the blood of patients after infusion
|
150 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01087294 |
100054 10-C-0054 |
|
February 5, 2010 |
March 1, 2023 |
March 1, 2024 |
March 16, 2010 |
April 19, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
26 |
NCT02644759 |
Recruiting |
Transplantation of Autologous Stem Cells for the Treatment of Type 1 Diabetes Mellitus |
- Diabetes Mellitus Type 1
- Autoimmune Diseases
- Endocrine System Diseases
- (and 3 more...)
|
- Biological: Stem Cell Transplantation
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Exogenous insulin dose
- Anti-GAD titres
- C-peptide level
- HbA1c level
|
100 |
All |
8 Years to 55 Years (Child, Adult) |
NCT02644759 |
SCA-DM1 |
|
February 2014 |
August 2018 |
January 2019 |
January 1, 2016 |
March 3, 2017 |
|
- Stem Cells Arabia
Amman, Jordan
|
27 |
NCT02641769 |
Recruiting |
Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility. |
- Non-obstructive Azoospermia
|
- Biological: Stem Cell Transplantation
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Appearance of different germ cells in testicles through the progress of spermatogenesis will be assessed by the count of cells using histological studies.
- General improvements of testicular morphology will be assessed with histological studies.
- Improvement in sexual function will be assessed using a questionnaire
|
50 |
Male |
21 Years to 50 Years (Adult) |
NCT02641769 |
SCA-INF1 |
|
January 2014 |
June 2018 |
January 2019 |
December 29, 2015 |
February 28, 2017 |
|
- Stem Cells of Arabia
Amman, Jordan
|
28 |
NCT01499888 |
Recruiting |
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) |
|
- Procedure: Allogeneic Non-Myeloablative Stem Cell Transplantation
- Drug: Alemtuzumab
- Drug: Sirolimus
|
Interventional |
Phase 1 Phase 2 |
- University of Illinois at Chicago
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the engraftment after non-myeloablative HSC transplant
- To assess the frequency of acute and chronic complications of sickle cell disease
- To evaluate the immune reconstitution after transplant.
- (and 2 more...)
|
15 |
All |
16 Years to 60 Years (Child, Adult) |
NCT01499888 |
2011-0096 |
|
November 11, 2011 |
May 2018 |
May 2018 |
December 26, 2011 |
April 20, 2017 |
|
- University of Illinois at Chicago
Chicago, Illinois, United States
|
29 |
NCT02844361 |
Recruiting |
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia |
- Waldenström Macroglobulinemia
|
- Other: autologous stem cell transplantation
- Other: conventional chemotherapy
|
Interventional |
Phase 4 |
- Institute of Hematology & Blood Diseases Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progress-free survival
- complete remission rate
|
70 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02844361 |
ITT2015006-EC-2 |
BDH-WM03 |
May 2016 |
November 2019 |
May 2020 |
July 26, 2016 |
July 26, 2016 |
|
|
30 |
NCT03023631 |
Recruiting |
HPV Antibody Response After GARDASIL 9 Vaccination in Participants After Allogeneic Stem Cell Transplantation |
|
|
Interventional |
Phase 4 |
- M.D. Anderson Cancer Center
- Merck Sharp & Dohme Corp.
- University Cancer Foundation
- Duncan Family Institute for Cancer Prevention and Risk Assessment
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Antibody Response
- Safety and Tolerability of GARDASIL 9 measured by Adverse events
- Antibody Persistence at 6 Months Post-Dose 3 Compared with 1 Month Post-Dose 3
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT03023631 |
2016-0714 2015 |
|
April 23, 2017 |
April 2019 |
April 2019 |
January 18, 2017 |
October 27, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
31 |
NCT03236220 |
Recruiting |
Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation |
- Haploidentical Hematopoietic Stem Cell Transplantation
|
- Drug: N-acetyl-L-cysteine
|
Interventional |
Phase 2 |
- Peking University People's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Incidence of poor graft function and prolonged isolated thrombocytopenia
- Number of participants with treatment-related adverse events will be assessed by CTCAE v4.0 during oral administration of NAC.
- Effect of NAC on hematopoietic stem cells, megakaryocytes and the elements of bone marrow microenvironment.
- (and 6 more...)
|
30 |
All |
15 Years to 60 Years (Child, Adult) |
NCT03236220 |
2015PHB220 |
|
August 1, 2017 |
July 2018 |
July 2019 |
August 1, 2017 |
August 9, 2017 |
|
- Peking University People's Hospital
Beijng, China
|
32 |
NCT02248597 |
Recruiting |
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases |
- Graft Versus Host Disease
- Hematopoietic/Lymphoid Cancer
|
- Drug: fludarabine phosphate
- Drug: busulfan
- Drug: cyclophosphamide
- (and 3 more...)
|
Interventional |
Phase 2 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 12 month disease free survival probability
- Rate of acute GvHD
- Rate of chronic GvHD
- (and 3 more...)
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT02248597 |
CCCWFU 97214 NCI-2014-01898 P30CA012197 |
|
January 2015 |
July 2018 |
July 2018 |
September 25, 2014 |
December 22, 2017 |
|
- Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, United States
|
33 |
NCT02605460 |
Recruiting |
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission |
- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia
|
- Drug: Busulfan
- Drug: Cyclophosphamide
- Drug: CXCR4 Antagonist
- Procedure: Hematopoietic Stem Cell Transplantation
|
Interventional |
Phase 2 |
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Disease Free Survival
|
20 |
All |
18 Years to 60 Years (Adult) |
NCT02605460 |
INCMNSZ REF 917 |
|
February 2014 |
June 2018 |
December 2018 |
November 16, 2015 |
November 13, 2017 |
|
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Distrito Federal, Mexico
|
34 |
NCT02670109 |
Recruiting |
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients |
- Triple-Negative Invasive Breast Carcinoma
- Residual Tumor
|
- Drug: Carmustine
- Drug: Cyclophosphamide
- Drug: Carboplatin
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
|
Interventional |
Phase 2 |
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Disease Free Survival
|
20 |
Female |
18 Years to 60 Years (Adult) |
NCT02670109 |
INCMNSZ REF 1239 |
|
November 2015 |
November 2018 |
November 2019 |
February 1, 2016 |
November 13, 2017 |
|
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Distrito Federal, Mexico
|
35 |
NCT03072849 |
Recruiting |
Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation |
- Bronchiolitis Obliterans Syndrome
|
- Procedure: Pulmonary function testing
- Drug: FAM Therapy
|
Observational |
|
- Ann & Robert H Lurie Children's Hospital of Chicago
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Lung function
- Survival
- Risk factor assessment
|
40 |
All |
6 Years to 18 Years (Child, Adult) |
NCT03072849 |
SCT 1214 BOS |
|
April 2015 |
April 2017 |
April 2019 |
March 7, 2017 |
March 7, 2017 |
|
- Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
|
36 |
NCT03159845 |
Recruiting |
Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies |
- Stem Cell Transplant Complications
|
- Drug: Zinc Sulfate Oral Product
- Drug: Levofloxacin 500Mg Oral Tablet
- Drug: Fluconazole 200mg tab
- Drug: Acyclovir 400 MG
|
Interventional |
Phase 2 |
- Azienda Ospedaliero, Universitaria Pisana
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Thymic output improvement by TRECs
- Thymic output improvement by flow cytometry
- Variations in circulating lymphocyte populations
- (and 2 more...)
|
50 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03159845 |
Hematology AOUPisa |
ZENITH |
January 1, 2014 |
January 1, 2018 |
January 1, 2021 |
May 19, 2017 |
June 12, 2017 |
|
|
37 |
NCT03431779 |
Recruiting |
Lipofilling as a Treatment for Vestibulodynia |
|
- Procedure: Adipose derived stem cell transplantation via lipofilling
- Procedure: Surgical excision
|
Interventional |
Not Applicable |
- University Hospital, Ghent
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Q-tip scores (Cotton swab assessment of vaginal pain) 3 months after surgery
|
30 |
Female |
18 Years to 85 Years (Adult, Senior) |
NCT03431779 |
B670201734071 |
|
February 20, 2018 |
December 2019 |
August 2020 |
February 13, 2018 |
February 13, 2018 |
|
- Ghent University Hospital
Ghent, Belgium
|
38 |
NCT02570542 |
Recruiting |
Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
- Diffuse Large B-cell Lymphoma (DLBCL)
- Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
- Procedure: leukapheresis
- Drug: Plerixafor
- Drug: carmustine, etoposide, cytarabine, melphalan
- Procedure: Autologous Stem Cell Transplantation
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Columbia University
- NorthShore University HealthSystem
- (and 5 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression-free survival (PFS)
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT02570542 |
15-193 |
|
October 2015 |
October 2018 |
October 2018 |
October 7, 2015 |
December 7, 2017 |
|
- Memoral Sloan Kettering Cancer Center Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Cancer Center Commack
Commack, New York, United States - (and 9 more...)
|
39 |
NCT03346135 |
Not yet recruiting |
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma |
- Plasma Cell Myeloma
- Secondary Amyloidosis
|
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Melphalan
- Biological: Daratumumab
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 2 |
- City of Hope Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Minimal residual disease (MRD) defined as if a positive result is obtained using the Adaptive MRD testing
- Incidence of adverse events graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03
- (and 5 more...)
|
34 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03346135 |
17189 NCI-2017-02087 |
|
September 2018 |
August 2019 |
August 2019 |
November 17, 2017 |
March 8, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States - Mayo Clinic
Rochester, Minnesota, United States - Levine Cancer Institute/Carolinas Health Care System
Charlotte, North Carolina, United States
|
40 |
NCT03225651 |
Recruiting |
Autologous Bone Marrow Stem Cell Therapy Combined With Psychological Therapy and Rehabilitation for Autism |
- Stem Cell Transplantation
|
- Biological: Stem cell transplantation
- Behavioral: Psychological therapy and Rehabilitation
|
Interventional |
Phase 2 |
- Vinmec Research Institute of Stem Cell and Gene Technology
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assess the change in autism level by using tools
- Evaluate the safety of therapy by record number of adverse events
|
60 |
All |
3 Years to 7 Years (Child) |
NCT03225651 |
VinmecRISCGT69 |
ASPRA |
January 18, 2017 |
December 18, 2018 |
December 18, 2018 |
July 21, 2017 |
July 21, 2017 |
|
- Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, Vietnam
|
41 |
NCT03286530 |
Recruiting |
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML |
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia in Remission
- Allogeneic Stem Cell Transplantation
|
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 1-year GVHD/relapse free survival rate (GRFS rate)
- Progression Free Survival
- Overall Survival
- (and 3 more...)
|
64 |
All |
60 Years to 80 Years (Adult, Senior) |
NCT03286530 |
17-273 |
|
November 3, 2017 |
September 1, 2020 |
September 1, 2024 |
September 18, 2017 |
April 13, 2018 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States
|
42 |
NCT01995578 |
Recruiting |
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse |
- Myelodysplastic Syndromes (MDS)
- Acute Myelogenous Leukemia (AML)
|
- Drug: low dose 5'-azacitidine
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- relapse rate
- overall survival
- safety
|
32 |
All |
1 Year to 75 Years (Child, Adult, Senior) |
NCT01995578 |
13-192 |
|
December 2013 |
November 2018 |
November 2018 |
November 26, 2013 |
November 17, 2017 |
|
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Commack
Commack, New York, United States - (and 3 more...)
|
43 |
NCT02671448 |
Recruiting |
Pilot Trial of Homebound Stem Cell Transplantation |
|
- Behavioral: Home monitoring teleconsult visits
- Behavioral: Patient Reported Outcomes (PRO)
- Behavioral: Caregiver Reported Outcomes instruments
|
Observational |
|
- Memorial Sloan Kettering Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- readmission rate by 21 days post HSCT
|
30 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02671448 |
15-022 |
|
January 2016 |
January 2019 |
January 2019 |
February 2, 2016 |
March 29, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
44 |
NCT03267433 |
Recruiting |
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission |
- CD20 Positive
- Mantle Cell Lymphoma
|
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Other: Laboratory Biomarker Analysis
- Biological: Rituximab
|
Interventional |
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS) in MCL patients in MRD-negative first remission who undergo auto-HCT followed by rituximab vs. maintenance rituximab alone
- Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- MRD status in MCL patients who were MRD-positive prior to auto-HCT
- (and 4 more...)
|
689 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03267433 |
EA4151 NCI-2016-01403 U10CA180820 |
|
August 29, 2017 |
January 31, 2027 |
January 31, 2032 |
August 30, 2017 |
December 8, 2017 |
|
- ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, United States
|
45 |
NCT03202628 |
Recruiting |
Ixazomib Citrate, Pomalidomide, Dexamethasone, and Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Multiple Myeloma |
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
|
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Dexamethasone
- Drug: Ixazomib Citrate
- (and 2 more...)
|
Interventional |
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival at 18 months (PFS18) defined as the proportion of patients alive and free from disease progression at 18 months from study entry
- Greater than or equal to (>=) very good partial response (VGPR) rate
- Incidence of adverse events graded according to the National Cancer Institute (NC) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4
- (and 2 more...)
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT03202628 |
MC168A NCI-2017-01145 P30CA015083 |
|
July 24, 2017 |
July 24, 2022 |
July 24, 2022 |
June 28, 2017 |
August 8, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
46 |
NCT02684162 |
Recruiting |
SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) |
- Leukemia
- Myeloproliferative Diseases
|
- Drug: SGI-110
- Procedure: Donor Lymphocyte Infusion
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Astex Pharmaceuticals
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response of Participants with Hematologic Malignancies Exhibiting Minimal Residual Disease (MRD) After Allogeneic Stem Cell Transplant (Allosct) and SGI-110
- Response of Participants with Hematologic Malignancies Who Have Relapsed After Allogeneic Stem Cell Transplant (Allosct) and SGI-110
- Relapse-Free Survival With SGI-110 as Maintenance Therapy in Patients with High Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Stem Cell Transplantation
|
90 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02684162 |
2015-0117 NCI-2016-00343 |
|
June 2016 |
June 2021 |
June 2022 |
February 17, 2016 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
47 |
NCT01701492 |
Recruiting |
Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation |
- Stem Cell Transplant During Childhood
- Allogeneic Bone Marrow Transplant During Childhood
|
- Other: Questionnaire
- Other: Neurocognitive Evaluation
|
Observational |
|
- St. Jude Children's Research Hospital
- St. Baldrick's Foundation
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Intelligence and academic achievement
- Performance in specific neuropsychologic domains.
- Psychosocial function
- Quality of life
|
400 |
All |
8 Years and older (Child, Adult, Senior) |
NCT01701492 |
XPD12-077 BMTPE3 |
|
October 19, 2012 |
March 2018 |
March 2018 |
October 5, 2012 |
October 31, 2017 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
48 |
NCT03333187 |
Recruiting |
Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability |
|
- Biological: Allogeneic stem cell transplantation
- Drug: Ruxolitinib continuous therapy
|
Interventional |
Phase 2 |
- Universitätsklinikum Hamburg-Eppendorf
- Novartis
- CTC North (CRO)
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event free survival
- Speen reduction
- Improvement of constitutional symptoms
- (and 15 more...)
|
155 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03333187 |
MMM 02 study / RuxoAlloStudy |
|
December 21, 2016 |
December 20, 2019 |
March 20, 2023 |
November 6, 2017 |
November 6, 2017 |
|
- Universitätsklinkum Aachen
Aachen, Germany - HELIOS Klinikum Berlin-Buch
Berlin, Germany - Universitätsklinikum Bonn
Bonn, Germany - (and 16 more...)
|
49 |
NCT01908777 |
Recruiting |
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma |
- T Cell Non-Hodgkin Lymphoma
|
- Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- University of Washington
- Weill Medical College of Cornell University
- H. Lee Moffitt Cancer Center and Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The progression-free survival of patients
- Progression Free Survival for patients with high risk histologies
- Toxicities
- (and 3 more...)
|
33 |
All |
16 Years and older (Child, Adult, Senior) |
NCT01908777 |
13-020 |
|
July 16, 2013 |
July 2018 |
July 2018 |
July 26, 2013 |
November 27, 2017 |
|
- Moffitt Cancer Center
Tampa, Florida, United States - Memoral Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - (and 6 more...)
|
50 |
NCT03032783 |
Recruiting |
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity |
- Hematopoietic and Lymphoid Cell Neoplasm
|
- Radiation: Total-Body Irradiation
- Procedure: Donor Lymphocyte Infusion
- Drug: Cyclophosphamide
- (and 3 more...)
|
Interventional |
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Incidence of graft failure
- Incidence of non-relapse mortality
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT03032783 |
16D.606 |
|
January 31, 2017 |
July 24, 2020 |
July 24, 2020 |
January 26, 2017 |
February 20, 2018 |
|
- Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|